BENITEC BIOPHARMA ($BNTC) is expected to release its quarterly earnings data on Wednesday, September 24th after market close, per Finnhub. Analysts are expecting revenue of $0 and earnings of -$0.28 per share.
You can see Quiver Quantitative's $BNTC stock page to track data on insider trading, hedge fund activity, congressional trading, and more.
BENITEC BIOPHARMA Insider Trading Activity
BENITEC BIOPHARMA insiders have traded $BNTC stock on the open market 6 times in the past 6 months. Of those trades, 6 have been purchases and 0 have been sales.
Here’s a breakdown of recent trading of $BNTC stock by insiders over the last 6 months:
- CAPITAL MANAGEMENT, LLC SUVRETTA has made 6 purchases buying 916,497 shares for an estimated $11,911,736 and 0 sales.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
BENITEC BIOPHARMA Hedge Fund Activity
We have seen 37 institutional investors add shares of BENITEC BIOPHARMA stock to their portfolio, and 20 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- INFINITUM ASSET MANAGEMENT, LLC removed 18,413,250 shares (-97.4%) from their portfolio in Q2 2025, for an estimated $215,435,025
- VANGUARD GROUP INC added 642,132 shares (+196.4%) to their portfolio in Q2 2025, for an estimated $7,512,944
- BLACKROCK, INC. added 534,264 shares (+289.7%) to their portfolio in Q2 2025, for an estimated $6,250,888
- SUSQUEHANNA INTERNATIONAL GROUP, LLP removed 208,368 shares (-92.2%) from their portfolio in Q2 2025, for an estimated $2,437,905
- GEODE CAPITAL MANAGEMENT, LLC added 181,391 shares (+77.6%) to their portfolio in Q2 2025, for an estimated $2,122,274
- FRANKLIN RESOURCES INC removed 159,283 shares (-5.6%) from their portfolio in Q2 2025, for an estimated $1,863,611
- STATE STREET CORP added 139,883 shares (+660.1%) to their portfolio in Q2 2025, for an estimated $1,636,631
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
BENITEC BIOPHARMA Analyst Ratings
Wall Street analysts have issued reports on $BNTC in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- Oppenheimer issued a "Outperform" rating on 09/16/2025
- HC Wainwright & Co. issued a "Buy" rating on 05/19/2025
- JMP Securities issued a "Market Outperform" rating on 05/15/2025
To track analyst ratings and price targets for BENITEC BIOPHARMA, check out Quiver Quantitative's $BNTC forecast page.
BENITEC BIOPHARMA Price Targets
Multiple analysts have issued price targets for $BNTC recently. We have seen 3 analysts offer price targets for $BNTC in the last 6 months, with a median target of $28.0.
Here are some recent targets:
- Andreas Argyrides from Oppenheimer set a target price of $29.0 on 09/16/2025
- Raghuram Selvaraju from HC Wainwright & Co. set a target price of $28.0 on 05/19/2025
- Silvan Tuerkcan from JMP Securities set a target price of $20.0 on 05/15/2025
This article is not financial advice. See Quiver Quantitative's disclaimers for more information. Note that there may be inaccuracies due to mistakes in ticker-mapping, and other anomalies.
